Cargando…

Methods and utility of quantitative brainstem measurements in progressive supranuclear palsy versus Parkinson's disease in a routine clinical setting

BACKGROUND AND PURPOSE: The clinical diagnosis of progressive supranuclear palsy can be challenging, as the clinical presentation overlaps with that of Parkinson's disease and multiple system atrophy. We sought to examine the practical utility of radiologic markers of progressive supranuclear p...

Descripción completa

Detalles Bibliográficos
Autores principales: Cooperrider, Jessica, Bluett, Brent, Jones, Stephen E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8298805/
https://www.ncbi.nlm.nih.gov/pubmed/34316619
http://dx.doi.org/10.1016/j.prdoa.2020.100033
_version_ 1783726129831477248
author Cooperrider, Jessica
Bluett, Brent
Jones, Stephen E.
author_facet Cooperrider, Jessica
Bluett, Brent
Jones, Stephen E.
author_sort Cooperrider, Jessica
collection PubMed
description BACKGROUND AND PURPOSE: The clinical diagnosis of progressive supranuclear palsy can be challenging, as the clinical presentation overlaps with that of Parkinson's disease and multiple system atrophy. We sought to examine the practical utility of radiologic markers of progressive supranuclear palsy by investigating whether these markers could distinguish between patients with progressive supranuclear palsy-Richardson syndrome (PSP-RS) and those with Parkinson's disease based on imaging obtained in a typical clinical setting, not in a prospective research environment. MATERIALS AND METHODS: This retrospective study included 13 patients with PSP-RS and 13 patients with Parkinson's disease who were followed for either condition at our institution at the time of the study and who had MRI records available. Patients were selected without regard to type of imaging obtained. All diagnoses were confirmed by a trained movement disorders specialist using validated diagnostic criteria. Groups were matched for age and disease duration at the time of scanning. MRI records were retrospectively obtained, and image analysis was performed by investigators blinded to disease classification. Midbrain area, midbrain to pons area ratio, midbrain anterior-posterior diameter, and MR parkinsonism index were calculated for each patient. RESULTS: All established measures of identifying progressive supranuclear palsy (midbrain area, midbrain to pons area ratio, midbrain anterior-posterior diameter, and MR parkinsonism index) were significantly different between patients with PSP-RS and those with Parkinson's disease. CONCLUSION: Previously established radiographic markers distinguishing between PSP-RS and Parkinson's disease have practical utility in the clinical setting and not just in well-designed prospective analyses.
format Online
Article
Text
id pubmed-8298805
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-82988052021-07-26 Methods and utility of quantitative brainstem measurements in progressive supranuclear palsy versus Parkinson's disease in a routine clinical setting Cooperrider, Jessica Bluett, Brent Jones, Stephen E. Clin Park Relat Disord Original Article BACKGROUND AND PURPOSE: The clinical diagnosis of progressive supranuclear palsy can be challenging, as the clinical presentation overlaps with that of Parkinson's disease and multiple system atrophy. We sought to examine the practical utility of radiologic markers of progressive supranuclear palsy by investigating whether these markers could distinguish between patients with progressive supranuclear palsy-Richardson syndrome (PSP-RS) and those with Parkinson's disease based on imaging obtained in a typical clinical setting, not in a prospective research environment. MATERIALS AND METHODS: This retrospective study included 13 patients with PSP-RS and 13 patients with Parkinson's disease who were followed for either condition at our institution at the time of the study and who had MRI records available. Patients were selected without regard to type of imaging obtained. All diagnoses were confirmed by a trained movement disorders specialist using validated diagnostic criteria. Groups were matched for age and disease duration at the time of scanning. MRI records were retrospectively obtained, and image analysis was performed by investigators blinded to disease classification. Midbrain area, midbrain to pons area ratio, midbrain anterior-posterior diameter, and MR parkinsonism index were calculated for each patient. RESULTS: All established measures of identifying progressive supranuclear palsy (midbrain area, midbrain to pons area ratio, midbrain anterior-posterior diameter, and MR parkinsonism index) were significantly different between patients with PSP-RS and those with Parkinson's disease. CONCLUSION: Previously established radiographic markers distinguishing between PSP-RS and Parkinson's disease have practical utility in the clinical setting and not just in well-designed prospective analyses. Elsevier 2020-01-14 /pmc/articles/PMC8298805/ /pubmed/34316619 http://dx.doi.org/10.1016/j.prdoa.2020.100033 Text en © 2020 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Article
Cooperrider, Jessica
Bluett, Brent
Jones, Stephen E.
Methods and utility of quantitative brainstem measurements in progressive supranuclear palsy versus Parkinson's disease in a routine clinical setting
title Methods and utility of quantitative brainstem measurements in progressive supranuclear palsy versus Parkinson's disease in a routine clinical setting
title_full Methods and utility of quantitative brainstem measurements in progressive supranuclear palsy versus Parkinson's disease in a routine clinical setting
title_fullStr Methods and utility of quantitative brainstem measurements in progressive supranuclear palsy versus Parkinson's disease in a routine clinical setting
title_full_unstemmed Methods and utility of quantitative brainstem measurements in progressive supranuclear palsy versus Parkinson's disease in a routine clinical setting
title_short Methods and utility of quantitative brainstem measurements in progressive supranuclear palsy versus Parkinson's disease in a routine clinical setting
title_sort methods and utility of quantitative brainstem measurements in progressive supranuclear palsy versus parkinson's disease in a routine clinical setting
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8298805/
https://www.ncbi.nlm.nih.gov/pubmed/34316619
http://dx.doi.org/10.1016/j.prdoa.2020.100033
work_keys_str_mv AT cooperriderjessica methodsandutilityofquantitativebrainstemmeasurementsinprogressivesupranuclearpalsyversusparkinsonsdiseaseinaroutineclinicalsetting
AT bluettbrent methodsandutilityofquantitativebrainstemmeasurementsinprogressivesupranuclearpalsyversusparkinsonsdiseaseinaroutineclinicalsetting
AT jonesstephene methodsandutilityofquantitativebrainstemmeasurementsinprogressivesupranuclearpalsyversusparkinsonsdiseaseinaroutineclinicalsetting